Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth

Purpose: We previously established a mechanistic rationale for Src inhibition as a novel therapeutic target in pancreatic cancer and have identified activated STAT3 as a potential biomarker of resistance to Src inhibition. The purpose of this study was to translate the current understanding of complementary activated tyrosine kinase signaling pathways by targeting Src kinase and epidermal growth factor receptor (EGFR). Experimental Design: IC50 values for dasatinib, a Src kinase inhibitor, erlotinib, an EGFR tyrosine kinase inhibitor and gemcitabine were determined and sensitive and resistant pancreatic cancer cell lines were identified. The in vitro and in vivo effects of these agents on multiple signaling pathways and tumorigenicity in pancreatic cancer were investigated. Results: The combination of dasatinib, erlotinib, and gemcitabine resulted in cooperative inhibition of cell migration and invasion of both sensitive and resistant pancreatic cancer cells as well as cooperative inhibition of multiple signaling pathways including FAK, AKT, ERK, JNK, MAPK, and STAT3 at concentrations that were ineffective as individual agents or as double combinations of agents. The triple combination of agents was also most effective at inhibiting the growth of xenografts of both sensitive and resistant pancreatic cancer cells in vivo without increasing toxicity. Furthermore, combined inhibition of Src and EGFR with gemcitabine inhibited constitutively activated STAT3 in vitro and in vivo. Conclusions: These results provide evidence that combined targeted biological therapy in addition to cytotoxic chemotherapy can overcome treatment resistance. Such treatment strategies may be used to tailor therapy based on identified biomarkers of resistance to targeted monotherapy. Clin Cancer Res; 17(3); 483–93. ©2011 AACR.

[1]  M. Washington,et al.  Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis , 2010, Molecular Cancer Therapeutics.

[2]  P. Yue,et al.  Enhanced Sensitivity of Pancreatic Cancer Cells to Concurrent Inhibition of Aberrant Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor or Src , 2010, Journal of Pharmacology and Experimental Therapeutics.

[3]  G. Mills,et al.  Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[4]  D. Wheeler,et al.  The role of Src in solid tumors. , 2009, The oncologist.

[5]  A. Jimeno,et al.  Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer , 2009, Clinical Cancer Research.

[6]  F. Rivera,et al.  Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. , 2009, Cancer treatment reviews.

[7]  L. Ellis,et al.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. , 2009, Cancer research.

[8]  M. Guba,et al.  Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling , 2008, Oncogene.

[9]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[10]  Andreas Hochhaus,et al.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Shadan Ali,et al.  Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer , 2008, Molecular Cancer Therapeutics.

[12]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[13]  B. LaFleur,et al.  TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer , 2008, Clinical Cancer Research.

[14]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[15]  R. Bruno,et al.  Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer , 2006, Clinical pharmacology and therapeutics.

[16]  F. Lee,et al.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. , 2006, The American journal of pathology.

[17]  A. Ryan,et al.  Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice , 2004, Clinical Cancer Research.

[18]  S. Courtneidge,et al.  The interplay between Src family kinases and receptor tyrosine kinases , 2004, Oncogene.

[19]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[20]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[21]  S. Ashley,et al.  siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. , 2004, Journal of the American College of Surgeons.

[22]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[23]  J. Turkson,et al.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.

[24]  G. Gillespie,et al.  Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. , 2002, Cancer research.

[25]  S. Parsons,et al.  Characterization of human epidermal growth factor receptor and c‐Src interactions in human breast tumor cells , 1998, Molecular carcinogenesis.

[26]  H. Friess,et al.  Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. , 1998, Biochemical and biophysical research communications.

[27]  M. T. Brown,et al.  Regulation, substrates and functions of src. , 1996, Biochimica et biophysica acta.

[28]  N. Lydon,et al.  Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α (*) , 1995, The Journal of Biological Chemistry.

[29]  H. Friess,et al.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. , 1992, The Journal of clinical investigation.

[30]  S. Parsons,et al.  c-Src, receptor tyrosine kinases, and human cancer. , 1999, Advances in cancer research.

[31]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.